Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Louisiana: - Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- Touro Infirmary — New Orleans, Louisiana
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Louisiana: - Tulane Cancer Center at EJGH — Metairie, Louisiana
- Tulane University School of Medicine — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Louisiana: - University Medical Center New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Louisiana: - Children's Hospital New Orleans — New Orleans, Louisiana
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Ochsner Health Ochsner Cancer Center - Baton Rouge — Baton Rouge, Louisiana
- Ochsner Clinic Foundation — New Orleans, Louisiana
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or …
Sponsor: AstraZeneca
NCT ID: NCT06627647
Sites in Louisiana: - Research Site — Alexandria, Louisiana
- Research Site — Baton Rouge, Louisiana
- Research Site — Shreveport, Louisiana
- Research Site — Shreveport, Louisiana
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Louisiana: - Research Site — Alexandria, Louisiana
- Research Site — Baton Rouge, Louisiana
- Research Site — Covington, Louisiana
- Research Site — Shreveport, Louisiana
- Research Site — Shreveport, Louisiana
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Louisiana: - LSU Health Baton Rouge North Clinic ( Site 4040) — Baton Rouge, Louisiana
- Our Lady of the Lake RMC-Clinical Research ( Site 4050) — Baton Rouge, Louisiana
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Louisiana: - Epic Medical Research - Monroe — Monroe, Louisiana
- Ochsner Medical Center — New Orleans, Louisiana
- Epic Medical Research - Shreveport — Shreveport, Louisiana
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Louisiana: - Local Institution - 2116 — New Orleans, Louisiana
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Louisiana: - Women's Cancer Care — Covington, Louisiana
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Louisiana: - LSU Health Shreveport — Shreveport, Louisiana
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in Louisiana: - Research Site — Shreveport, Louisiana
Phase 1 Recruiting Industry
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…
Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in Louisiana: - Ochsner Health — Jefferson, Louisiana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana: - Massive Bio SYNERGY-AI site — New Orleans, Louisiana
NA Recruiting Academic/Other
This study aims to reduce disparities and the burden of lung cancer among African American smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation (MILS), followed the NIH DEIA strategies…
Sponsor: Louisiana State University Health Sciences Center in New Orleans
NCT ID: NCT07576595
Sites in Louisiana: - LSUHSC School of Public Health — New Orleans, Louisiana
- University Medical Center — New Orleans, Louisiana